The center announced financial support to three firms in the public sector to increase production of indigenously developed COVID-1, capped by covaxin manufacturer Bharat Biotech as well as Hafkin Bio-Pharmaceutical Corporation, Indian Immunological and Bharat Immunological and Biological 19 Vaccines. .
The current production capacity of Kovaxin will double by May-June and will increase by about 6-7 times by July-August 2021. In other words, the current capacity of 10 million doses a month will increase to 6-7 crore a month. In July – August. A release from the Union Ministry of Science and Technology said that by September, about 100 million doses are expected to reach a month.
As part of the growth plan, Bharat Biotech’s production capacity as well as public sector vaccine manufacturers are being upgraded with the necessary infrastructure and technology.
In a grant to Bharat Biotech, which is remodeling its new facility in Bengaluru to increase the capacity of Kovaxin. 65 crores are being provided.
Hafken Bio-Pharmaceutical, a Maharashtra government undertaking, will provide approximately ine 65 crore in grants to build its facility to manufacture vaccines. While the company sought approximately 12 months to complete the task, being ready to manufacture the vaccine, the center asked for it to be completed within six months and to complete the process. Once functional, The Halfkin Facility will have a capacity of 20 million doses a month, the release said.
The center will also support Hyderabad-based Indian immunologists, which is a part of the National Dairy Development Board, as well as a CPSE under the Department of Biotechnology, Bharat Immunological and Biological (BIB Coal), to prepare its facilities. Provide 10–15 million doses a month from August – September.
The release said as part of the Atmanibhar Bharat 3.0 mission COVID protection, the Department of Biotechnology is providing financial support in the form of a grant for vaccine manufacturing facilities for enhanced production capacity. Without mentioning the firm’s names, it said that a few weeks ago inter-ministry teams visited the sites of the two main vaccine manufacturers in India. The visit was to seek their exchange on how production could be enhanced.
Kovaxin and Covicil, made by the Serum Institute of India, are two vaccines being used as part of a vaccination program against COVID-19 that India rolled out in mid-January. The Drugs Controller General of India (DCGI) recently released the Russian vaccine Sputnik V. Dr. Reddy’s Laboratories, the marketing partner for Sputnik V, recently stated that the imported vaccine will be available this quarter.
.
Add Comment